Meta Platforms
META
Alphabet-C
GOOG
Alphabet-A
GOOGL
Vale SA
VALE
Coinbase
COIN
US Stock MarketDetailed Quotes
CTXR Citius Pharmaceuticals
- 3.3000
- +0.1500+4.76%
Close Jan 24 16:00 ET
- 3.2800
- -0.0200-0.61%
Post 19:09 ET
28.36MMarket Cap-0.55P/E (TTM)
3.4000High3.0200Low165.49KVolume3.0200Open3.1500Pre Close543.05KTurnover2.11%Turnover RatioLossP/E (Static)8.59MShares26.750052wk High0.40P/B25.87MFloat Cap2.440052wk Low--Dividend TTM7.84MShs Float750.0000Historical High--Div YieldTTM12.06%Amplitude2.4400Historical Low3.2810Avg Price1Lot Size
About Citius Pharmaceuticals Company
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.
Company Profile
SymbolCTXR
Company NameCitius Pharmaceuticals
Listing DateAug 3, 2017
Issue Price4.13
Founded2007
CEOMr. Leonard L. Mazur
MarketNASDAQ
Employees23
Fiscal Year Ends09-30
Address11 Commerce Drive,1st floor
CityCranford
ProvinceNew Jersey
CountryUnited States of America
Zip Code07016
Phone1-908-967-6677
Websitehttp://www.citiuspharma.com
Company Executives
- Name
- Position
- Salary
- Leonard L. Mazur
- Executive Chairman of the Board, Chief Executive Officer and Secretary; Secretary of NoveCite, Inc. and President and Chief Executive Officer of Citius Oncology, Inc.
- 1.98M
- Jaime Bartushak
- Chief Financial Officer, Principal Accounting Officer and Chief Business Officer
- --
- Dr. Myron Czuczman, M.D.
- Chief Medical Officer and Executive Vice President
- 1.17M
- Myron Z. Holubiak
- Executive Vice Chairman of the Board
- 1.59M
- Suren G. Dutia
- Lead Independent Director
- 196.97K
- Dennis M. McGrath, C.P.A.
- Independent Director
- 150.13K
- Carol Webb
- Independent Director
- 190.97K
- Dr. Eugene Holuka
- Independent Director
- 190.97K
- Robert J. Smith
- Independent Director
- --
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.